Rapidly Progressive Glomerulonephritis Diagnosis and Management

Clinical Definition and Presentation

• Rapidly progressive glomerulonephritis (RPGN) is characterized by rapid decline in kidney function over days to weeks, typically with extensive crescent formation (usually >50% of glomeruli) on kidney biopsy, according to the Kidney International guidelines 1, 2, 3

Diagnostic Approach

• Urinalysis showing urine dipstick positive for protein and blood, with sediment demonstrating glomerular hematuria and/or pyuria without infection, is a key diagnostic step in RPGN, as recommended by Kidney International 1, 4, 5
• Autoimmune serologies including ANCA, ANA, anti-GBM antibodies, and complement levels are essential in the diagnostic workup of RPGN, according to Kidney International 1, 6, 7
• Kidney biopsy is crucial to confirm diagnosis and assess disease activity versus chronicity in RPGN, as stated in Kidney International 1

Major Etiologic Categories

• ANCA-associated vasculitis (AAV) is the most common cause of rapidly progressive kidney failure, accounting for a significant proportion of RPGN cases, according to Kidney International 1, 4, 6
• Anti-GBM antibody glomerulonephritis is another major etiologic category of RPGN, as reported in Kidney International 1, 6, 7

Clinical Significance

• Early diagnosis and prompt initiation of immunosuppressive therapy, such as induction with cyclophosphamide or rituximab plus glucocorticoids for AAV, are critical for favorable outcomes in RPGN, as recommended by Kidney International and the American College of Nephrology 1, 4, 8
• Exclusion of infection before starting significant immunosuppression is essential in the management of RPGN, according to Kidney International 1, 5, 7

Rapidly Progressive Glomerulonephritis (RPGN) Causes and Diagnosis

Primary Etiologic Categories

• The National Kidney Foundation suggests that pauci-immune RPGN, characterized by ANCA-associated vasculitis, accounts for approximately 50-60% of RPGN cases, with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) being common causes 9, 10
• The American Society of Nephrology notes that approximately 90% of patients with pauci-immune RPGN have detectable ANCA antibodies (MPO or PR3), though ANCA negativity does not exclude the diagnosis 10
• The European Renal Association states that anti-GBM antibody disease (Goodpasture's Syndrome) accounts for approximately 20% of RPGN cases, often presenting with pulmonary-renal syndrome (simultaneous lung and kidney injury) 9, 10
• The International Society of Nephrology reports that immune complex-mediated RPGN accounts for approximately 20-25% of RPGN cases, with IgA nephropathy with extensive crescent formation being a common cause 11, 12, 13

Critical Diagnostic Distinction

• The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends that true RPGN requires both histologic crescents AND rapid deterioration of kidney function over days to weeks, with the presence of crescents alone on kidney biopsy without a concomitant rapid decline in GFR not constituting RPGN 11, 13

Common Clinical Pitfall

• The American College of Rheumatology advises that immunosuppressive therapy should not be delayed while waiting for kidney biopsy results if clinical presentation is compatible with small-vessel vasculitis and MPO- or PR3-ANCA serology is positive, especially in rapidly deteriorating patients 10

Rapid Progressive Glomerulonephritis Diagnostic Approach and Treatment

Introduction to Diagnostic Considerations

• The Kidney International guideline recommends hepatitis B and C serologies before starting immunosuppression in patients with RPGN 14

Treatment Approach

• The American Journal of Kidney Diseases recommends starting treatment immediately with a regimen similar to ANCA-associated vasculitis for crescentic/necrotizing RPGN, including pulse IV methylprednisolone and either cyclophosphamide or rituximab 15, 16
• The Kidney International guideline suggests treating HCV-associated RPGN with cryoglobulinemic flare using both direct-acting antivirals and immunosuppressive agents, with or without plasma exchange 14

Considerations for Immunotherapy

• The American Journal of Kidney Diseases guideline advises withholding immunosuppression if eGFR <30 mL/min per 1.73 m² with chronic changes, unless there is active necrotizing/crescentic GN or preserved renal parenchyma with acute tubular necrosis 15, 16
• The Kidney International guideline emphasizes the importance of excluding active infection, including hepatitis B, before starting immunosuppression 14

Rapidly Progressive Glomerulonephritis Diagnosis and Treatment

Clinical Presentation and Diagnosis

• The KDIGO guidelines recognize that RPGN can occur in nephrotic syndrome, particularly in idiopathic MPGN with nephrotic syndrome and progressive decline in kidney function, which warrants immunosuppressive therapy with cyclophosphamide or MMF plus corticosteroids 17
• RPGN can also occur in lupus nephritis presenting with nephrotic-range proteinuria and crescentic changes 17
• The guidelines indicate that indications for immunosuppressive therapy include active nephritic syndrome, or rapidly progressive disease, with or without crescents, as well as nephrotic syndrome with or without progressive decline in kidney function 17

Treatment Approach

• The treatment approach for RPGN is determined by the underlying pathology, not by whether the patient initially presented with nephritic versus nephrotic features 17

Immune Complex‑Mediated Causes of Rapidly Progressive Glomerulonephritis

IgA Vasculitis (Henoch‑Schönlein Purpura)

• In patients with immune‑complex mediated RPGN, IgA vasculitis (Henoch‑Schönlein purpura) is recognized as a major etiologic contributor, accounting for a notable proportion of cases with granular immunoglobulin deposition on renal biopsy【18】.

Membranoproliferative Glomerulonephritis with Crescents

• Membranoproliferative glomerulonephritis (MPGN) that presents with crescent formation is another important cause of immune‑complex mediated RPGN, characterized by granular immune deposits and often associated with underlying infections or complement dysregulation【18】.